Search
for
Sort by
Research 451–480 of 1000+
- Cardiodermatology: the heart of the connection between the skin and cardiovascular disease
- Twenty-Nail Dystrophy Treated with Hydroxychloroquine in a Patient with Alopecia Areata
- Clinical Perspectives on Alopecia: From Hair Follicle Biology to Advanced Therapies
- Impacto del desequilibrio del microbioma del cuero cabelludo en la severidad de la alopecia areata, marcadores inflamatorios y cambios post-tratamiento
- Dupilumab: Friend or Foe to Alopecia Areata?
- An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature
- Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
- Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
- Current and future pharmacotherapy for alopecia areata
- Pharmacotherapy of alopecia areata
- AP-2α/AP-2β transcription factors are key regulators of epidermal homeostasis
- Roles of tumor suppressors in regulating tumor-associated inflammation
- Treatment of Alopecia Areata in Mice by Stimulating the Hair Follicles Using Parathyroid Hormone Agonists Linked to a Collagen Binding Domain
- Endocrine Regulation of Hair Growth and Loss: Current Evidence and Clinical Implications
- Tissue engineering strategies for human hair follicle regeneration: How far from a hairy goal?
- JAK inhibitors in dermatology: The promise of a new drug class
- BH19 ‘JAK in the box?’ Long-term safety concerns with oral Janus kinase inhibitors for alopecia areata
- Association of JAK 1 and JAK 2 gene polymorphism with alopecia areata risk: a case–control genetic study
- JAK Inhibitors for Treatment of Alopecia Areata
- Multiomic Characterization of Treatment Response to JAK Inhibition in Patients with APECED
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
- The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies
- JAK inhibition decreases the autoimmune burden in Down syndrome
- JAK inhibition decreases the autoimmune burden in Down syndrome
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- Screening for latent infectious disease in patients with alopecia areata before initiating JAK inhibitors therapy: a single-center real-world retrospective study
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Short-term Efficacy of Tofacitinib, a JAK Inhibitor, in IFIH1-related Aicardi-Goutières Syndrome
- LB1034 Meta-analysis of scalp transcriptome defines alopecia areata subtypes and molecular response to four (4) treatments with jak inhibiting properties